·3828
ers for hepatocellular carcinoma[J]. J Clin Gastroenterol, 2011, 45(4) :355 360.
Haybaeck J,Zeller N, Heikenwalder M, The parallel universe; Mi
[14]
croRNAs and their role in chronie hepatitis, liver tissue damage and hepatocareinogenesis [J]. Swiss Med Wkly, 2011, 14 (1) : 13287.
[15][16][17]
[18][19]
Tomimaru Y,Eguchi H,Nagano H,et al. Circulating microRNA 21 as a novel biomarker for hepatocetlular carcinoma[J]. J Hepa tol,2012,56(1) :167 175.
Shen J,Stass SA,Jiang F. MieroRNAs as potential biomarkers in human solid tumors[J]. Cancer Lett,2013,32(9) :125 136. Callegari E,Elamin BK,Ssabbioni S,et al. Role of microRNAs in hepatoeetlular carcinoma: A clinicial perspective [J]. Onco Tar gets Ther,2013,6(4) :1167 1178.
Tian Q,Liang L, Ding J,et al. miRNA 500 acts as a pro meta static gene and directly targets cytoplasmic polyadenylation ele-ment binding protein 4 in bepalocellular carcinoms [ J]. PLeS One,2012,7(11) :e48958.
Wei Liqing, Li Ying, Hu Jianhua, et al. Dysregulation of microR
且仙梅，等
血小板增多与非小细胞肺癌关系的研究进展
NA 500 expression in development process from hepatitis C liver einhosis to liver cancer[ J]. Chin J Exp Surg,2014,6(31 ) :1316-1317.[魏礼清，李颖，胡建华，等.循环微小RNA-500在丙型肝炎肝硬化到肝癌病程中的表达J].中华实验外科杂志， 2014,6(31) :1316 1317. )
[20][2]
[22]
He XX, Chang Y, Meng FY,et al. MicroRNA - 375 targets AEC 1 in hepatocellular carcinoma and suppresses liver canoer cell growth in vitro and in vivo[ J]. Oneogene,2012,31(28) ; 3357 3369.
Guo Xiaodong, Yu Lingxiang, Yang Mei,et al. Expression and sig-nificance of miR 224 in serum on primary hepatocellular carci-noma[J]. Progress in Modern Biomed,2014,14 (4) :621 623.【郭晓东，余灵样，杨美，等.miR-224在原发性肝癌惠者血清中的表达及意义[J].现代生物医学进展，2014,14(4)：621-623.]
Li LM,Hu ZB,Zhou ZX,et al. Serum microRNA profiles serve as novel biomarkem for HBV infection and diagnosis of HBV positive hepatocarcinoma[J]. Cancer Res,2010,70(23) :9798 9807.,
（编校：葡期）
血小板增多与非小细胞肺癌关系的研究进展吕仙梅"，袁霞妹"，郭秋生？
Thrombocytosisandnon-smallcelllungcancer Lv Xianmei', Yuan Xiamei', Guo Qiusheng
'Department of Oncology;"Department of Abdominal Surgical Oncology,Jinhua Guangfu Tumor Hospital,Zhejiang Jinhua 321000, China.
[ Abstract]This article introduces the definition, incidence,mechanism of thrombocytosis in the non small cell lung cancer,and correlation with the clinical stage and prognosis,as well as anti platelet in the treatment of lung cancer.[ Key words] non small cell lung cancer, thrombocytosis, anti platelet
Modem Oncology 2016,24(23) :3828 3830
【指示性摘要】闹述非小细胞肺瘤合并血小板增多症的定义、发生率、与临床分期及预后关系，以及血小板增多的发生机制及抗血小板治疗的运用。
【关键词】非小细胞肺癌；血小板增多症；抗血小板治疗
【中图分类号]R734.2
【文献标识码】A
【文章编号]16724992(2016)23382803
原发性肺癌为世界范围内最常见的恶性肿瘤之一。其中非小细胞肺癌约占肺瘤总数的70%~80%。根据我国卫生统计年鉴显示，肺癌死亡率占我国恶性肿瘤死亡率第位。多种因素影响非小细胞肺癌患者的预后。国内外许多
【收稿日期】【作者单位】
【作者简介】
2016 03 27
1浙江金华广福肿瘤医院肿瘤内科；"腹部肿瘤外科，浙江金华321000
吕仙梅（1984－），女，江西人，主治医师，硕士，主要从事肿瘤内科工作。Email;echo15304423@163.com
DOI;10. 3969/j. issn. 1672 4992. 2016. 23. 040
研究显示血小板计数与非小细胞肺癌预后相关，血小板增多者预后不良。
血液循环中的血小板计数异常增高称为血小板增多症，常持续大于450×10°/L。临床上有原发性（essentialthrom-bocytosis，ET）和继发性（reactive thrombocytosis，RT）的区别。前者又称为特发性血小板增多症，为造血干细胞克隆性疾病，患者中约50%~70%有JAK2/V617F基因突变。继发性血小板增多常见于恶性肿瘤、慢性炎性改变、急性感染恢复期、大量出血后、缺铁性贫血、脾切除术后或使用肾上腺素